Visual outcomes of age-related macular degeneration patients undergoing intravitreal ranibizumab monotherapy in an urban population

Figures & data

Table 1 Comparison of present study demographics and mean baseline vision to pivotal trials

Demographics	Presentstudy	CATT trial	ANCHOR trial	MARINA trial
Age
Mean (years)	83	79	76	77
Largest group (years)	80–89	70–79	75–84	75–84
Sex
Male (%)	51	40	54	37
Female (%)	49	59	46	63
Ethnicity
Caucasian (%)	62	98	97	97
Other (%)	38	3	4	3
Mean baseline vision (ETDRS letters)	35

Abbreviation: ETDRS, Early Treatment Diabetic Retinopathy Study.

Figure 1 Graph comparing the visual outcomes after 1 year from this study to the CATT, ANCHOR, and MARINA trials.

Abbreviation: ETDRS, Early Treatment Diabetic Retinopathy Study.

Figure 2 Graph comparing the visual outcomes after 2 years from this study to the CATT, ANCHOR, and MARINA trials.

Abbreviation: ETDRS, Early Treatment Diabetic Retinopathy Study.

Table 2 Comparison of present study visual outcomes and number of ranibizumab treatments to pivotal trials

Visual outcomes	Present study	CATT trial	ANCHOR trial	MARINA trial
12 months
Maintained vision: loss of less than 15 ETDRS letters (% of eyes)	91.8	96.0	96.4	94.6
Improved vision: gain of 15 or more ETDRS letters (% of eyes)	20.3	25.0	40.3	33.8
Worsened vision: loss of more than 15 ETDRS letters (% of eyes)	8.1	4.0	3.60	5.4
Mean number of treatments	6	6.9	12	12
24 months
Maintained vision: loss of less than 15 ETDRS letters (% of eyes)	88.6	93.0	90.0	90.0
Improved vision: gain of 15 or more ETDRS letters (% of eyes)	19.7	33.0	41.0	35.0
Worsened vision: loss of more than 15 ETDRS letters (% of eyes)	11.5	7.0	4.0	6.0
Mean number of treatments	4	5.7	12	12

Abbreviation: ETDRS, Early Treatment Diabetic Retinopathy Study.

Figure 3 A graph comparing the mean visual progression of this study to the CATT, ANCHOR, and MARINA trials

Abbreviations: CMH, Central Middlesex Hospital; ETDRS, Early Treatment Diabetic Retinopathy Study.

Figure 4 A graph comparing the mean visual acuity of this study to the CATT, ANCHOR, and MARINA trials.

Abbreviation: VA, visual acuity.

Figure 5 A graph comparing the visual outcomes of this study to ten other single-center studies of real-life populations.

Abbreviation: ETDRS, Early Treatment Diabetic Retinopathy Study.

Table 3 Comparison of present study results to ten other studies of real life AMD populations treated with ranibizumab monotherapy around the world

	Present study UK	Bandukwala et al^Citation13 Canada	Cohen et al^Citation10 France	Dadgostar et al^Citation11 USA	Feng et al^Citation17	Małgorzata and Stankiewicz^Citation8 Poland	Hjelmqvistet al^Citation16 Sweden	Kang et al^Citation14 Korea	Querques et al^Citation12 France	Shienbaum et al^Citation9 USA	Subramanian et al^Citation15 USA
Number of eyes	123 (year 1) 61 (year 2)	95	124	131	93	25	370	64	96	7	7
Mean age (years)	83	81	78	81	80	73	78	70	77	81	80
Sex
Male (%)	59	37	30	35.5	41.5	44	30	72	29	N/A	86
Female (%)	41	63	70	64.5	58.5	56	60	28	71		14
Maintained vision: loss of less than 15 ETDRS letters (%)	91.8 (year 1) 88.6 (year 2)	82	90	83.8	84.9	100	89.1	85.9	94.8 (year 1) 87.5 (year 2)	100	85
Improved vision: gain of more than 15 ETDRS letters (%)	20.3 (year 1) 19.7 (year 2)	11	8	30	25.8	32	14.7	N/A	26 (year 1) 25 (year 2)	60	N/A
Worsened vision: loss of more than 15 ETDRS letters (%)	8.1 (year 1) 11.5 (year 2)	18	2	15	15	0	10.9	14.1	12.5 (years 1 and 2)	0	15
Mean number of ranibizumab injections	6 (year 1) 4 (year 2)	5.1	3.79	5.2	4.3	6	4.7	4.2	6.4	4.7	4
Mean visual acuity change (ETDRS letters)	3.5 (year 1) 3 (year 2)	2.5	3.5	5	N/A	10.6	1	1	5.5 (year 1) 5.1 (year 2)	17	6.3
Follow-up period (months)	24	12	12	12	11	12	12	12	24	12	12
Retrospective or prospective	P	R	R	R	R	R	R	R + P	R	R	P

Abbreviations: AMD, age-related macular degeneration; ETDRS, Early Treatment Diabetic Retinopathy Study; N/A, not applicable; P, prospective; R, retrospective.

BandukwalaTMuniRHSchwartzCEngKTKertesPJEffectiveness of intravitreal ranibizumab for the treatment of neovascular age-related macular degeneration in a Canadian retina practice: a retrospective reviewCan J Ophthalmol201045659059521135894

 PubMed Web of Science ®Google Scholar

CohenSYDuboisLTadayoniRResults of one-year’s treatment with ranibizumab for exudative age-related macular degeneration in a clinical settingAm J Ophthalmol2009148340941319477713

 PubMed Web of Science ®Google Scholar

DadgostarHVenturaAAChungJYSharmaSKaiserPKEvaluation of injection frequency and visual acuity outcomes for ranibizumab monotherapy in exudative age-related macular degenerationOphthalmology200911691740174719643484

 PubMed Web of Science ®Google Scholar

FengXFConstableIJMcAllisterILIsaacsTComparison of visual acuity outcomes between ranibizumab and bevacizumab treatment in neovascular age-related macular degenerationInt J Ophthalmol201141858822553617

 PubMed Web of Science ®Google Scholar

MałgorzataFStankiewiczAEffectiveness of ranibizumab intravitreal injections for exudative age-related macular degeneration treatment: 12-month outcomesMed Sci Monit2011179CR48549021873944

 PubMed Web of Science ®Google Scholar

HjelmqvistLLindbergCKanulfPDahlgrenHJohanssonISiewertAOne-year outcomes using ranibizumab for neovascular age-related macular degeneration: results of a prospective and retrispective observational multicentre studyJ Ophthalmol2011201140572422174994

 PubMed Web of Science ®Google Scholar

KangSRohYJOne-year results of intravitreal ranibizumab for neovascular age-related macular degeneration and clinical responses of various subgroupsJpn J Ophthalmol200953438939519763757

 PubMed Web of Science ®Google Scholar

QuerquesGAzryaSMartinelliDRanibizumab for exudative age-related macular degeneration: 24 month outcomes from a single centre institutional settingBr J Ophthalmol201094329229619951942

 PubMed Web of Science ®Google Scholar

ShienbaumGGarcia FilhoCAFlynnHWJrNunesRPSmiddyWERosenfeldPJManagement of submacular hemorrage secondary to neovascular age-related macular degeneration with anti-vascular endothelial growth factor monotherapyAm J Ophthalmol201315561009101323465269

 PubMed Web of Science ®Google Scholar

SubramanianMLAbediGNessSBevacizumab vs ranibizumab for age-related macular degeneration: 1-year outcomes of a prospective, double-masked randomised clinical trialEye (Lond)2010241708171520885427

 PubMed Web of Science ®Google Scholar